Bonolive® clinical results will be presented during the 13th European Congress on Osteoporosis and Osteoarthritis in Rome
Bonolive® clinical results will be presented during the 13th European Congress on Osteoporosis and Osteoarthritis in Rome
Press release
Bonolive® is a clinically proven bone health supplement. A randomized, double-blind, placebo-controlled study proved that Bonolive® has significant benefits on bone mineral density, osteoblast activity and blood lipid profile. The results of this clinical study will be presented by dr. Veronique Coxam during the congress of the International Osteoporosis Foundation in Rome next April 17-20th, 2013.
The results of the clinical trial
Bonolive® is a natural polyphenol extract from olive leaves which supports healthy bones. A randomized, double-blind, placebo-controlled study showed that Bonolive® has significant benefits on bone mineral density (BMD) (DEXA scan), osteoblast activity (bone formation marker osteocalcin) and blood lipid profile. A 12-month administration of (Bonolive®) resulted in:
•Significantly higher levels of osteocalcin (+32%)
•Significantly lower triglycerides, total and LDL-cholesterol
•A stabilization of lumbar spine BMD in the treatment group
The results of this study will be presented by Dr. Veronique Coxam, Head of the Group Micronutrients at INRA, Centre de Theix. She has done pioneering work on the relationship between micronutrients and bone health. She is co-inventor of the patent covering the use of polyphenolics from olive for the prevention of osteoporosis. The presentation will be held at the 13th European Congress on Osteoporosis and Osteoarthritis.
The International Osteoporosis Foundation (IOF) and ESCEO have worked in partnership for several years to develop a unique European springtime meeting program for healthcare professionals, researchers and young scientists: the 13th European Congress on Osteoporosis and Osteoarthritis in Rome. The presentation of the Bonolive® study results will be held on Saturday April 20 at 11.1011.20 in the Auditorium A (Salone Dei Cavalieri / Level -1). There will also be the opportunity to ask questions. Additional information regarding the Congress on Osteoporosis and Osteoarthritis can be obtained from: www.ecceo13-iof.org. Additional information on Bonolive® and scientific study results can be obtained from www.bonolive.com.
About BioActor
BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.
Feel free to contact us via info@bioactor.com for more information on the possibilities Bonolive® has to offer.
Further information can be found on: www.bonolive.com
